Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00802113
Other study ID # AAAA5185
Secondary ID CHNY-01-501
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date June 2003
Est. completion date October 22, 2014

Study information

Verified date March 2019
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The sequential combination of myeloablative therapy and autologous stem cell transplantation (APBSCT) followed by a reduced intensity allogeneic stem cell transplant (Allo SCT) and post SCT adoptive cellular immunotherapy will be well tolerated in patients with refractory or recurrent non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).


Description:

Lymphomas are the third most common group of cancers in children and adolescents in the United States. While Hodgkin's Disease (HD) has been described for many years, some subtypes of the non-Hodgkin's Lymphomas (NHL) have only recently been described. Non-Hodgkin's lymphomas traditionally have been classified as low, intermediate or high grade based on their clinical aggressiveness. More recently they have been divided into two major subgroups indolent and aggressive lymphomas by the current National Cancer Institute (NCI/PDQ) reference. Among children, aggressive histologies are prevalent including small non-cleaved cell lymphoma, lymphoblastic lymphoma, and diffuse large cell lymphoma. The most common histologic classifications of childhood non-Hodgkin's lymphoma over the past 30 years has included the morphological schema developed by Rappaport, the morphologically and immunologically based schema of Lukes and Collins, the Kiel classifications, the prognostic sub-groupings of the National Cancer Institute's Working Formulation, and the most recently developed classification that utilizes morphological, immunophenotypic and genetic information in the Revised European-American Lymphoma (REAL) classification.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date October 22, 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender All
Age group N/A to 55 Years
Eligibility Inclusion Criteria:

Patient must have adequate organ function as below

- Adequate renal function defined as:

1. Serum creatinine less than or equal to 2.0 x normal, or

2. Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 40 ml/min/m2 or >60 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range

- Adequate liver function defined as:

1. Total bilirubin <2.0 x normal; or

2. Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase (AST)) or serum glutamic-pyruvic transaminase (SPGT) (alanine aminotransferase (ALT)) <5.0 x normal

- Adequate cardiac function defined as:

1. Shortening fraction of >27% by echocardiogram, or

2. Ejection fraction of >47% by radionuclide angiogram or echocardiogram

- Adequate pulmonary function defined as:

1. Diffusing capacity of the lungs for carbon monoxide (DLCO) >50% by pulmonary function test for autologous transplant

2. DLCO > 40% by pulmonary function test for reduced intensity allogeneic transplant

3. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry >94% in room air.

Disease Status (Eligibility)

- Patients with Non-Hodgkin's Lymphoma with either of the following:

1. Primary induction failure (failure to achieve initial CR) who have a partial response (PR) or stable disease (SD) with reinduction chemotherapy. *All patients are required to have a biopsy regardless of positron emission tomography (PET)/Gallium results.

2. Patients with 1st PR, 2nd CR, 2nd PR, or 2nd SD following reinduction chemotherapy

3. Patients with 3rd CR, 3rd PR, 3rd SD following reinduction chemotherapy

- Patients with Hodgkin's Disease with either of the following:

1. Primary induction failure (failure to achieve initial CR) and/or primary refractory disease.

2. First relapse

1. Early relapse (within 12 months off therapy) (excluding those who received no therapy or radiation therapy only for initial therapy)

2. Late relapse (greater than 12 months off therapy). Only patients with recurrent Stage III or IV disease and/or those with B symptoms at relapse (all other late relapses are excluded).

3. Second relapse.

4. Third relapse.

- Patients must achieve a CR, PR or SD after reinduction chemotherapy.

Exclusion Criteria:

- Patients with NHL or HD with 4th or greater CR, PR, and/or SD

- Patients with progressive disease (PD) unresponsive to reinduction chemo, radio, or immunotherapy

- Hodgkin's Disease in late relapse (other than those discussed above).

- Patients with post-transplant lymphoproliferative disease following a solid organ transplantation or AIDS associated NHL

- Patients who don't have an eligible donor

- Women who are pregnant

Study Design


Intervention

Drug:
Fludarabine
Fludarabine 30 mg/m2 x 5 days
Busulfan
Busulfan 3.2 mg/kg/day x 2 days
Anti-Thymocyte Globulin
Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days

Locations

Country Name City State
United States Children's Memorial Hospital in Chicago Chicago Illinois
United States Duke University Durham North Carolina
United States Hackensack University Medical Center Hackensack New Jersey
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Columbia University Medical Center New York New York
United States New York Medical College Valhalla New York

Sponsors (1)

Lead Sponsor Collaborator
Columbia University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) Complete Response is defined as the complete resolution of B symptoms (i.e., weight loss, night sweats and fever) and normalization of all sites of disease on the basis of physical exam, bone marrow biopsy, and imaging studies. Up to 1 year post-transplantation
Primary Total Number of Subjects With a Disease Relapse or Progression Following MAC AutoSCT Includes subjects with any measurable growth of disease in a previously affected site or detection of disease in a new site confirmed by biopsy. Up to 1 year post-transplantation
Primary Total Number of Subjects With Partial Response or Stable Disease Following MAC AutoSCT Total includes subjects with partial response and patients with stable disease, defined as <50% reduction in measurable disease or the uninterrupted persistence of B symptoms. Up to 1 year post-transplantation
Secondary Time to Neutrophil Engraftment Following MAC AutoSCT, the median time to neutrophil (PMN) recovery will be measured. Up to 1 year post-transplantation
Secondary Time to Platelet Engraftment Following MAC AutoSCT, the median time to platelet recovery will be measured. Up to 1 year post-transplantation
Secondary Total Number of Subjects With Grade II-IV Acute Graft-versus-Host-Disease (GVHD) The criteria for grading is based on extent of organ involvement (i.e., Skin, Liver and Gut - rash on >50% of skin, bilirubin 2-3 mg/dl, diarrhea > 500 ml/day) with Grade II being better outcome and Grade IV being worse outcome. Up to 1 year post-transplantation
Secondary Total Number of Subjects That Experienced Transplant-related Mortality (TRM) Status as subjects died post-AlloHCT Up to 1 year post-transplantation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT01878890 - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. Phase 1
Completed NCT04152148 - A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients Phase 1
Recruiting NCT05096234 - 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma Phase 2
Recruiting NCT05191225 - Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study Phase 4
Recruiting NCT05623982 - Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03664635 - MB-CART20.1 Lymphoma Phase 1/Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Terminated NCT01699581 - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant Phase 2
Completed NCT01763398 - Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study N/A
Completed NCT01205503 - Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00969462 - Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Phase 4
Completed NCT00659425 - CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma Phase 1
Completed NCT00608907 - An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) Phase 1
Withdrawn NCT00577161 - Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL Phase 3
Terminated NCT00475332 - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Phase 2
Completed NCT00533728 - Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma Phase 1
Completed NCT00430352 - MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Phase 4
Completed NCT00581646 - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance N/A